PR Newswire

Albumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences

Recombumin, an animal and human origin free recombinant albumin, is an excipient in the final formulation of Heartseed's HS-001 treatment. In February 2023, Heartseed announced successful dosing of HS ...
Mena FN

Albumedix And Heartseed Announce Recombumin® As A Critical Excipient In The Manufacture Of Heartseed's HS-001 Investigational Cell Therapy As Its First In-Human Trial Commences

(MENAFN- PR Newswire) NOTTINGHAM, England, March 14, 2023 /PRNewswire/ -- Albumedix Ltd ('Albumedix'), Nottingham, United Kingdom, now part of the global life science group Sartorius, and Heartseed ...